{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:18:17Z","timestamp":1789154297011,"version":"build-2803163510"},"reference-count":112,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Chronic lymphocytic leukemia (CLL) treatment has undergone a significant evolution with a shift from historical chemotherapeutic regimens to targeted therapies such as Bruton tyrosine kinase (BTK) and BCL-2 inhibitors. These advancements have been associated with a notable improvement in survival rates with a transformation of CLL into a chronic and manageable condition for most persons with this disease. However, as a consequence of improved outcomes, long-term CLL survivors now face emergent challenges which include a risk of infections, cardiovascular complications, and secondary malignancies. In this changed scenario, holistic models of care are essential to address emergent health risks. Such models of care for CLL patients require a multidisciplinary approach that integrates CLL treatment with the proactive management of frailty, comorbidities, and psychosocial well-being to enhance both survival and quality of life (QoL). CLL predominantly affects older persons, many of whom present with concurrent frailty and comorbidities that may complicate CLL treatment and impact QoL. Comprehensive geriatric assessments (GA) may play a critical role in the identification of persons at a heightened risk of treatment-related toxicity and may help guide rational therapy selection, particularly in very frail persons. In addition to the assessment of hematological responses, the prospective assessment of patient-reported outcomes (PROs) and frailty metrics may offer a more nuanced understanding of the global treatment benefits. A survivorship-focused care model is crucial to address the multifaceted needs of CLL patients with the extension of patient care into the broader domain of long-term health maintenance with associated improvements in QoL.<\/jats:p>","DOI":"10.3390\/cancers17010119","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T06:05:10Z","timestamp":1735797910000},"page":"119","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Chronic Lymphocytic Leukemia Care and Beyond: Navigating the Needs of Long-Term Survivors"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2795-6507","authenticated-orcid":false,"given":"Stefano","family":"Molica","sequence":"first","affiliation":[{"name":"Department of Hematology, Hull University Teaching Hospitals NHS Trust, Hull HU3 2JZ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6159-6109","authenticated-orcid":false,"given":"David","family":"Allsup","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hull University Teaching Hospitals NHS Trust, Hull HU3 2JZ, UK"},{"name":"Centre for Biomedicine, Hull York Medical School, University of Hull, Hull HU6 7RX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"key":"ref_1","unstructured":"(2024, December 30). SEER*Explorer: An Interactive Website for SEER Cancer Statistics, Available online: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0140-6736(24)00595-6","article-title":"Chronic lymphocytic leukaemia","volume":"404","author":"Jain","year":"2024","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41408-022-00728-z","article-title":"Survival trends in hematological malignancies in the Nordic countries through 50 years","volume":"12","author":"Hemminki","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41408-022-00669-7","article-title":"Long-term trends in the loss in expectation of life after a diagnosis of chronic lymphocytic leukemia: A population-based study in the Netherlands, 1989-2018","volume":"12","author":"Maas","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41408-021-00556-7","article-title":"Survival of patients with chronic lymphocytic leukemia before and after the introduction of chemoimmunotherapy in Germany","volume":"11","author":"Wellmann","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41408-021-00532-1","article-title":"Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index","volume":"11","author":"Wang","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1200\/JCO.23.02738","article-title":"Chronic Lymphocytic Leukemia: Time to Care for the Survivors","volume":"42","author":"Fedele","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","article-title":"Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial","volume":"370","author":"Catovsky","year":"2007","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","article-title":"Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia","volume":"107","author":"Eichhorst","year":"2006","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2006.08.0762","article-title":"Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997","volume":"25","author":"Flinn","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1200\/JCO.2011.39.2688","article-title":"Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"30","author":"Fischer","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1182\/blood.2023020158","article-title":"Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up","volume":"142","author":"Thompson","year":"2023","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood.2023021954","article-title":"Functional cure reported in CLL","volume":"142","author":"Davids","year":"2023","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1038\/s41375-020-0959-x","article-title":"COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: A joint study by ERIC, the European Research Initiative on CLL, and CLL Campus","volume":"34","author":"Chatzikonstantinou","year":"2020","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/hon.2990","article-title":"Current perspectives regarding SARS-CoV-2 vaccination in chronic lymphocytic leukemia","volume":"40","author":"Molica","year":"2022","journal-title":"Hematol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: Updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","article-title":"ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia","volume":"35","author":"Eichhorst","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_22","unstructured":"(2024, December 30). Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Version 1.2025\u2014October 1, 2024 Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cll.pdf."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: First-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in firstline treatment of chronic lymphocytic leukaemia (iLLUMINATE): A multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.3324\/haematol.2021.279012","article-title":"First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: Final analysis of the randomized, phase III iLLUMINATE trial","volume":"107","author":"Moreno","year":"2022","journal-title":"Haematologica"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versu chemoimmunotherapy in older patients with untreated CLLN","volume":"379","author":"Woyach","year":"2018","journal-title":"Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1182\/blood.2023021959","article-title":"Long-term results of Alliance A041202 show continued advantage of ibrutinib-based regimens compared with bendamustine plus rituximab (BR) chemoimmunotherapy","volume":"143","author":"Woyach","year":"2024","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): A randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood-2023-174750","article-title":"Acalabrutinib \u00b1 obinutuzumab vs obinutuzumab + chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia: 6-year follow-up of Elevate-TN","volume":"142","author":"Sharman","year":"2023","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and smalllymphocytic lymphoma (SEQUOIA): A randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/s41467-023-37648-w","article-title":"Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_36","first-page":"S1","article-title":"Final Analysis of the RESONATE-2 Study: Up to 10 Years of Follow-Up of First-Line Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma","volume":"24","author":"Burger","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk. Vol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1002\/hem3.74","article-title":"First-line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age-matched general population: A pooled post hoc analysis","volume":"8","author":"Ghia","year":"2024","journal-title":"Hemasphere"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/ajh.27182","article-title":"Impact of targeted agents on survival of CLL patients age > 65 relative to age and sex matched population","volume":"99","author":"Molica","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2015-03-567388","article-title":"Perturbation of the normal immune system in patients with CLL","volume":"126","author":"Forconi","year":"2015","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2012.187","article-title":"Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): A cohort study of newly diagnosed cases compared to controls","volume":"27","author":"Moreira","year":"2013","journal-title":"Leukemia"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Galitzia, A., Maccaferri, M., Mauro, F.R., Murru, R., and Marasca, R. (2024). Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents. Cancers, 16.","DOI":"10.3390\/cancers16111996"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Vassilopoulos, S., Shehadeh, F., Kalligeros, M., Tran, Q.L., Schiffman, F., and Mylonakis, E. (2022). Targeted therapies in CLL\/SLL and the cumulative incidence of infection: A systematic review and meta-analysis. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.989830"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/infdis\/jiae106","article-title":"Immunologic Predictors of Vaccine Responsiveness in Patients With Lymphoma and Chronic Lymphocytic Leukemia","volume":"230","author":"Chong","year":"2024","journal-title":"J. Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/ajh.27093","article-title":"The evolving landscape of, COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL","volume":"98","author":"Visentin","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1016\/S1473-3099(18)30601-7","article-title":"Vaccination of patients with haematological malignancies who did not have transplantations: Guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Mikulska","year":"2019","journal-title":"Lancet Infect Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1080\/10428194.2023.2258243","article-title":"Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with, CLL","volume":"64","author":"Tomasulo","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"106432","DOI":"10.1016\/j.leukres.2020.106432","article-title":"Ibrutinib restores immune cell numbers and function in first-line and relapsed\/refractory chronic lymphocytic leukemia","volume":"97","author":"Solman","year":"2020","journal-title":"Leuk. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1182\/bloodadvances.2023010236","article-title":"Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: The phase 2 CAPTIVATE study","volume":"7","author":"Moreno","year":"2023","journal-title":"Blood Adv."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1002\/cncr.29438","article-title":"Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes","volume":"121","author":"Parikh","year":"2015","journal-title":"Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Khan, S., Allsup, D., and Molica, S. (2023). An updated perspective on immunoglobulin replacement in chronic lymphocytic leukaemia in the era of targeted therapies. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1135812"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/bloodadvances.2022008073","article-title":"Interventions to reduce infections in patients with hematological malignancies: A systematic review and meta-analysis","volume":"7","author":"Chai","year":"2023","journal-title":"Blood Adv."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1111\/bjh.16859","article-title":"High prevalence and incidence of cardiovascular disease in chronic lymphocytic leukaemia: A nationwide population-based study","volume":"190","author":"Larsson","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"E255","DOI":"10.1002\/ajh.26558","article-title":"Cardiovascular disease in patients with chronic lymphocytic leukemia: A Swedish nationwide register study with matched comparators","volume":"97","author":"Larsson","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib initiation","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Fernandez Turizo, M.J., Kim, E., Zhang, C., Yankama, T., Von Keudell, G., Sermer, D.J., Mej\u00edas-De Jes\u00fas, C., and Asnani, A. (2024). Pre-existing cardiovascular disease is associated with an increased risk of cardiovascular events during Bruton tyrosine kinase inhibitor therapy. Oncologist, oyae229. Online ahead of print.","DOI":"10.1093\/oncolo\/oyae229"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","volume":"102","author":"Brown","year":"2017","journal-title":"Haematologica"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jaccao.2023.02.001","article-title":"Ibrutinib Is Associated With Increased Cardiovascular Events and Major Bleeding in Older CLL Patients","volume":"5","author":"Diamond","year":"2023","journal-title":"JACC CardioOncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: Results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: The ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1182\/blood.2024024667","article-title":"Sustained Benefit of Zanubrutinib vs Ibrutinib in Patients With R\/RCLL\/SLL: Final Comparative Analysis of ALPINE","volume":"144","author":"Brown","year":"2024","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","article-title":"Ventricular arrhythmias and sudden death in patients taking ibrutinib","volume":"129","author":"Lampson","year":"2017","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/bjh.19469","article-title":"Analysis of ventricular arrhythmias and sudden death from prospective, randomized clinical trials of acalabrutinib","volume":"205","author":"Sharman","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jaccao.2023.09.002","article-title":"Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: JACC: CardioOncology State-of-the-Art Review","volume":"5","author":"Quartermaine","year":"2023","journal-title":"JACC CardioOncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1200\/JCO.21.00693","article-title":"Cardiovascular risk associated with ibrutinib use in chronic lymphocytic leukemia: A population-based cohort study","volume":"39","author":"Sabrie","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Zheng, Y., Guo, X., Chen, C., Chi, L., Guo, Z., Liang, J., Wei, L., Chen, X., Ye, X., and He, J. (2023). Cardiovascular Toxicities of Ibrutinib: A Pharmacovigilance Study Based on the United States Food and Drug Administration Adverse Event Reporting System Database. Pharmaceuticals, 16.","DOI":"10.3390\/ph16010098"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3324\/haematol.2021.278901","article-title":"Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: Pooled analysis of 762 patients","volume":"107","author":"Brown","year":"2022","journal-title":"Haematologica"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1182\/bloodadvances.2022007938","article-title":"International consensus statement on the management of cardiovascular risk of Bruton\u2019s tyrosine kinase inhibitors in CLL","volume":"6","author":"Awan","year":"2022","journal-title":"Blood Adv."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"AlAsmari, A.F., Alghamdi, A., Ali, N., Almeaikl, M.A., Hakami, H.M., Alyousef, M.K., AlSwayyed, M., Alharbi, M., Alqahtani, F., and Alasmari, F. (2022). Venetoclax Induces Cardiotoxicity through Modulation of Oxidative-Stress-Mediated Cardiac Inflammation and Apoptosis via NF-\u0152\u222bB and BCL-2 Pathway. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23116260"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/bloodadvances.2022007333","article-title":"Cardiac events in patients with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents","volume":"6","author":"Johnson","year":"2022","journal-title":"Blood Adv."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41408-019-0237-1","article-title":"Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-023-00784-z","article-title":"Risk of second primary malignancies in patients with chronic lymphocytic leukemia: A population-based study in the Netherlands, 1989\u20132019","volume":"13","author":"Levin","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"102307","DOI":"10.1016\/j.eclinm.2023.102307","article-title":"Other malignancies in the history of CLL: An international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY","volume":"65","author":"Chatzikonstantinou","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3324\/haematol.2015.124693","article-title":"Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: A meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG)","volume":"100","author":"Cramer","year":"2015","journal-title":"Haematologica"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1038\/s41375-020-0987-6","article-title":"Second cancer incidence in CLL patients receiving BTK inhibitors","volume":"34","author":"Bond","year":"2020","journal-title":"Leukemia"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/annonc\/mdw072","article-title":"Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia","volume":"27","author":"Falchi","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e488","DOI":"10.3324\/haematol.2016.148858","article-title":"Increased risk of axial fractures in patients with untreated chronic lymphocytic leukemia: A population-based analysis","volume":"101","author":"Olszewski","year":"2016","journal-title":"Haematologica"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1182\/blood.V100.4.1215.h81602001215_1215_1219","article-title":"The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia","volume":"100","author":"Ferrajoli","year":"2002","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/cncr.10772","article-title":"Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia","volume":"95","author":"Lai","year":"2002","journal-title":"Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1182\/blood-2011-03-342436","article-title":"Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia","volume":"118","author":"Yan","year":"2011","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1158\/0008-5472.CAN-12-2280","article-title":"RANKL expression, function, and therapeutic targeting in multiple myeloma and chronic lymphocytic leukemia","volume":"73","author":"Schmiedel","year":"2013","journal-title":"Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1182\/blood-2010-07-295683","article-title":"Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia","volume":"117","author":"Shanafelt","year":"2011","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.leukres.2011.10.004","article-title":"Vitamin D insufficiency predicts time to first treatment (TFT) in early chronic lymphocytic leukemia (CLL)","volume":"36","author":"Molica","year":"2012","journal-title":"Leuk. Res."},{"key":"ref_85","first-page":"S101","article-title":"Vertebral fractures in patients with B-cell chronic lymphocytic leukemia before and after ibrutinib treatment. XX International workshop on chronic lymphocytic leukemia","volume":"64","author":"Jaksic","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"100201","DOI":"10.1016\/j.bonr.2019.100201","article-title":"Bruton\u2019s tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption","volume":"10","author":"Ariza","year":"2019","journal-title":"Bone Rep."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/JPER.18-0334","article-title":"A novel Bruton\u2019s tyrosine kinase inhibitor, acalabrutinib, suppresses osteoclast differentiation and Porphyromonas gingivalis lipopolysaccharide-induced alveolar bone resorption","volume":"90","author":"Pokhrel","year":"2019","journal-title":"J. Periodontol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Giannoni, P., Marini, C., Cutrona, G., Sambuceti, G.M., Fais, F., and de Totero, D. (2023). Unraveling the Bone Tissue Microenvironment in Chronic Lymphocytic Leukemia. Cancers, 15.","DOI":"10.3390\/cancers15205058"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1586\/17474086.2013.814845","article-title":"Treatment of elderly patients with chronic lymphocytic leukemia: An unmet cinical need","volume":"6","author":"Molica","year":"2013","journal-title":"Expert. Rev. Hematol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/17474086.2024.2366534","article-title":"Defining treatment success in chronic lymphocytic leukemia: Exploring surrogate markers, comorbidities, and patient-centered endpoints","volume":"17","author":"Molica","year":"2024","journal-title":"Expert. Rev. Hematol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1182\/blood.2023021370","article-title":"Frailty is also a target for targeted drugs in CLL","volume":"142","author":"Goede","year":"2023","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1182\/blood.2023020195","article-title":"Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL","volume":"142","author":"Stege","year":"2023","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e3249","DOI":"10.1002\/hon.3249","article-title":"Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort","volume":"42","author":"Martino","year":"2024","journal-title":"Hematol. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/hon.3164_344","article-title":"Safety of acalabrutinib treatment in very old (\u226580 y) and\/or frail patients with chronic lymphocytic leukemia\u2014interim safety analysis of the ongoing phase II CLL-Frail trial","volume":"41","author":"Simon","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Gasc\u00f3n-Y-Mar\u00edn, I., Ballesteros-Andr\u00e9s, M., Mart\u00ednez-Flores, S., Rodr\u00edguez-Vicente, A.E., P\u00e9rez-Carretero, C., Quijada-\u00c1lamo, M., Rodr\u00edguez-S\u00e1nchez, A., and Hern\u00e1ndez-Rivas, J.\u00c1. (2023). The Five \u201cWs\u201d of Frailty Assessment and Chronic Lymphocytic Leukemia: Who, What, Where, Why, and When. Cancers, 15.","DOI":"10.3390\/cancers15174391"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jgo.2022.08.010","article-title":"Associations among frailty and quality of life in older patients with cancer treated with chemotherapy","volume":"13","author":"Crowder","year":"2022","journal-title":"J. Geriatr. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"101538","DOI":"10.1016\/j.jgo.2023.101538","article-title":"Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia","volume":"14","author":"Johnson","year":"2023","journal-title":"J. Geriatr. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Soumerai, J.D., Barrientos, J.C., Ahn, I.E., Coombs, C.C., Gladstone, D.E., Hoffmann, M.S., Kittai, A.S., Jacobs, R.W., Lipsky, A., and Patel, K. (Blood Adv, 2024). Consensus Recommendations from the 2024 Lymphoma Research Foundation Workshop on Treatment Selection Sequencing in CLL or SLL, Blood Adv.","DOI":"10.1182\/bloodadvances.2024014474"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/ejh.13943","article-title":"The net clinical benefit of targeted agents in the upfront treatment of elderly\/unfit chronic lymphocytic leukemia patients: Results of network meta-analysis","volume":"110","author":"Molica","year":"2023","journal-title":"Eur. J. Haematol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2141.2007.06791.x","article-title":"Quality of life in chronic lymphocytic leukemia: An international survey of 1482 patients","volume":"139","author":"Shanafelt","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1600-0609.2004.00233.x","article-title":"Quality of life of patients with chronic lymphocytic leukemia: Results of a longitudinal investigation over 1 yr","volume":"72","author":"Holzner","year":"2004","journal-title":"Eur. J. Haematol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1080\/03007995.2020.1784120","article-title":"Health-related quality of life and economic burden of chronic lymphocytic leukemia in the era of novel targeted agents","volume":"36","author":"Waweru","year":"2020","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e13678","DOI":"10.1111\/ecc.13678","article-title":"Examining anxiety and depression in haematology cancer patients in ongoing treatment and under watchful waiting: A systematic review and meta-analysis","volume":"31","author":"Russell","year":"2022","journal-title":"Eur. J. Cancer Care"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Fifer, S., Godsell, J., Opat, S., Hamad, N., Lasica, M., Forsyth, C., Morand, L., Smeaton, E., Winton, S., and Puig, A. (2024). Understanding the experience, treatment preferences and goals of people living with chronic lymphocytic leukemia (CLL) in Australia. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12589-9"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Deering, K.L., Sundaram, M., Harshaw, Q., Trudeau, J., and Barrientos, J.C. (2022). Health-related quality of life and treatment satisfaction in Chronic Lymphocytic Leukemia (CLL) patients on ibrutinib compared to other CLL treatments in a real-world US cross sectional study. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0270291"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1080\/03007995.2023.2262378","article-title":"Health-related quality of life outcomes associated with zanubrutinib versus ibrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: Results from the ALPINE Trial","volume":"39","author":"Tam","year":"2023","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_107","first-page":"EP1743","article-title":"Living with chronic lymphocytic leukemia (CLL): A quantitative cross-sectional study of italian patients\u2019 experiences on behalf of ail (associazione italiana contro le leucemie-linfomi e mielomi)","volume":"4","author":"Molica","year":"2020","journal-title":"EPOSTER"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Molica, S., Shanafelt, T.D., Allsup, D., and Giannarelli, D. (2024). Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched Population. Cancers, 16.","DOI":"10.3390\/cancers16061085"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Villavicencio, A., Solans, M., Zacar\u00edas-Pons, L., Vidal, A., Puigdemont, M., Roncero, J.M., Saez, M., and Marcos-Gragera, R. (2021). Comorbidities at Diagnosis, Survival, and Cause of Death in Patients with Chronic Lymphocytic Leukemia: A Population-Based Study. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18020701"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1182\/asheducation.V2007.1.324.324","article-title":"Comprehensive management of the CLL patient: A holistic approach","volume":"2007","author":"Shanafelt","year":"2007","journal-title":"Hematology Am. Soc. Hematol. Educ. Program."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11912-020-0881-4","article-title":"Revolution of Chronic Lymphocytic Leukemia Therapy: The Chemo-Free Treatment Paradigm","volume":"22","author":"Scheffold","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1093\/oncolo\/oyad324","article-title":"Treatment Patterns, Healthcare Resource Utilization, and Costs of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the US","volume":"29","author":"Yang","year":"2024","journal-title":"Oncologist"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/1\/119\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T15:23:42Z","timestamp":1759850622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/1\/119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":112,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["cancers17010119"],"URL":"https:\/\/doi.org\/10.3390\/cancers17010119","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]}}}